Navigation Links
St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
Date:4/9/2013

to reduce the pain and anxiety children and parents face in stressful situations such as administering stitches, mending lacerations, or helping with broken bones.  N2O has few side effects and is very fast acting. 

Beyond patient and physician considerations, input from area ambulance squads was also incorporated into design decisions including a covered ambulance entrance and lounge area to protect these first respondents from bad weather, as well as a squad room to relax and refresh in before their next call.

Phase 3 will focus on renovating the pre-existing Emergency Department and Trauma Center and adding the finishing touches to the department.  It is scheduled to be completed this summer.  In this final phase, the Bristol-Myers Squibb Pediatric Emergency Care Center will grow from eight to 11 beds and add separate infectious and noninfectious reception areas.  Features such as doors in treatment rooms and the addition of a pediatric resuscitation room that can also be used for pediatric trauma are among the new features to be added.

The major component that differentiates a Trauma Center from an emergency care facility is the requirement for 24-hour availability of a team of specially trained healthcare providers with expertise in treating severely injured patients.  St. Mary has the only state accredited Trauma Center in Bucks County and has full access to a wide range of highly advanced diagnostic services.  It is one of 31 regional trauma centers to meet the tough standards required for accreditation in the Commonwealth of Pennsylvania by the Pennsylvania Trauma Systems Foundations (PTSF).  The Trauma Center includes state-of-the-art trauma bays with immediate access to diagnostic services and a sterile operating-room environment.  Trauma patients are given priority admission and immediate access to full services, includin
'/>"/>

SOURCE St. Mary Medical Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... December 22, 2014 The Center ... leader of technical training across the life sciences industry, ... Management (SCDM) to provide the organization's members with ... —providing access to the more than 350 sessions across ... with 10% off when registering for a public ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Site, ST. LOUIS, Sept. 26 ... SIAL ), has announced a $29 ... capabilities in,high-potency biologics at the Sigma-Aldrich facility ... SAFC Pharma(TM) to provide process,development and cGMP ...
... 26 PAREXEL International,Corporation (Nasdaq: PRXL ... announced the successful completion of the acquisition,of ... ("APEX") in,a separate press release. In conjunction ... the Company is updating its forward-looking,financial guidance ...
... Inc.,(Nasdaq: ITMN ) today announced that it ... stock at a price to the public of ... representing the exercise,by the underwriters of their option ... proceeds to the company of the offering are ...
Cached Biology Technology:SAFC to Expand High-Potency API Fermentation Capabilities 2SAFC to Expand High-Potency API Fermentation Capabilities 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 4InterMune Announces Closing of Public Offering of Common Stock 2
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... the Uniformed Services University of the Health Sciences ... the National Cancer Institute (NCI) have made a ... viruses that could be engineered for use as ... the Nipah and Hendra viruses--naturally occurring and highly ...
... of molecular signals that instructs cells with fatally damaged DNA ... p53 is inactivated, as it is in over half of ... to operate, and body cells start to accumulate mutations, which ... this vital safeguard has been studied in great detail for ...
... relatively new cancer drug can survive an otherwise lethal ... report scientists supported by the National Institute of Allergy ... of Health. The findings, say the investigators, suggest that ... adverse side effects of smallpox vaccine. The classic smallpox ...
Cached Biology News:Discovery could be key to bioterrorism defense 2Discovery could be key to bioterrorism defense 3Cancer related gene p53 not regulated as indicated by previous tissue culture research 2Cancer related gene p53 not regulated as indicated by previous tissue culture research 3Cancer drug slows poxvirus in mice 2Cancer drug slows poxvirus in mice 3
... of the Axima range, the AXIMA-CFR ... accuracy, resolution, sensitivity and mass range, ... linear and reflectron time-of-flight analysis. The ... the generation of seamless PSD, providing ...
... new MALDI O-TOF creates a new category ... orthogonal platform that has been licensed to ... of Manitoba. , As the first single ... and collisional cooling, the prOTOF 2000 represents ...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
Biology Products: